Recombinant Human CSF1R

• Cat.No.: CSF1R-28792TH
• Product Overview: Recombinant fragment, corresponding to amino acids 539-972 (Cytoplasmic domain) of Human MCSF Receptor, with an N-terminal enzyme tag.Expressed by baculovirus in Sf9 insect cells.

Specification

• Description: The protein encoded by this gene is the receptor for colony stimulating factor 1, a cytokine which controls the production, differentiation, and function of macrophages. This receptor mediates most if not all of the biological effects of this cytokine. Ligand binding activates the receptor kinase through a process of oligomerization and transphosphorylation. The encoded protein is a tyrosine kinase transmembrane receptor and member of the CSF1/PDGF receptor family of tyrosine-protein kinases. Mutations in this gene have been associated with a predisposition to myeloid malignancy. The first intron of this gene contains a transcriptionally inactive ribosomal protein L7 processed pseudogene oriented in the opposite direction.
• Tissue specificity: Expressed in bone marrow and in differentiated blood mononuclear cells.
• Biological activity: Specific activity 21 nmol/min/mg.
• Form: Liquid
• Storage buffer: Preservative: NoneConstituents: 25% Glycerol, 50mM Tris HCl, 150mM Sodium chloride, 0.25mM DTT, 0.1mM EGTA, 0.1mM EDTA, 0.1mM PMSF, pH 7.5
• Storage: Shipped on dry ice. Upon delivery aliquot and store at -80oC. Avoid freeze / thaw cycles.
• Sequence Similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.Contains 5 Ig-like C2-type (immunoglobulin-like) domains.Contains 1 protein kinase domain.
• Tag: Non

Gene Information

• Gene Name: CSF1R colony stimulating factor 1 receptor [ Homo sapiens ]
• Official Symbol: CSF1R
• Synonyms: CSF1R; colony stimulating factor 1 receptor; FMS, McDonough feline sarcoma viral (v fms) oncogene homolog; macrophage colony-stimulating factor 1 receptor; C FMS; CD115; CSFR
• Gene ID: 1436
• mRNA Refseq: NM_005211
• Protein Refseq: NP_005202
• MIM: 164770
• Uniprot ID: P07333
• Chromosome Location: 5q32
• Pathway: C-MYB transcription factor network, organism-specific biosystem; Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; Endocytosis, organism-specific biosystem; Endocytosis, conserved biosystem
• Function: ATP binding; cytokine binding; cytokine binding; macrophage colony-stimulating factor receptor activity; nucleotide binding

Reviews

01/09/2022

With its remarkable quality, reliability, and the manufacturer's excellent technical support, I am confident that it will be an invaluable asset in driving my scientific inquiries forward and facilitating groundbreaking discoveries in my field.

10/30/2017

This variety allows me to select the most appropriate option based on the specific requirements of my research.

03/10/2017

the manufacturer's commitment to quality control and rigorous testing guarantees the reliability and reproducibility of the CSF1R protein, which is essential for obtaining accurate and consistent results.

Q&As

Are there any FDA-approved drugs targeting CSF1R for clinical use?

Yes, drugs like pexidartinib have been approved for the treatment of certain rare tumors called tenosynovial giant cell tumors (TGCT) that overexpress CSF1R.

How can CSF1R inhibitors impact the tumor microenvironment?

CSF1R inhibitors can modulate the tumor microenvironment by reducing the number of tumor-associated macrophages and promoting an anti-tumor immune response.

Can CSF1R inhibitors be used in combination with other cancer treatments?

Yes, CSF1R inhibitors are often used in combination with chemotherapy and immunotherapy to enhance treatment effectiveness.

What are the potential clinical applications of CSF1R inhibitors?

CSF1R inhibitors are being investigated for cancer therapy to block tumor-promoting macrophages and slow down cancer progression.

Can CSF1R inhibitors be used to treat neurodegenerative diseases?

Research is ongoing, and CSF1R inhibitors are being explored as a potential therapy for neurodegenerative diseases, but no FDA-approved treatments currently exist.